Investors who might be interested in the biotech sector could consider the Ocugen Inc (NASDAQ: OCGN) stock at this point.
The stock might have declined earlier on this week and there was important news with regards to Bharat Biotech, its Indian partner, which might be of interest to bullish investors. Earlier in the week, it emerged that Bharat Biotech started the rollout of its COVID-19 vaccine and there were reports that there were side effects.
In addition to side effects, there were also reports about the shortage of vaccines in India. In this regard, it is also necessary to mention that Bharat Biotech could also become subject to investigations with regards to its side effects. However, the company is now looking to boost its monthly production and eventually come up with 5 million to 12 million doses by July this year. Bharat Biotech announced that it has been awarded the requisite regulatory licenses. In this situation, investors could consider keeping an eye on the company’s United States partner Ocugen.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.